Armata Wins FDA Support to Advance Bacteriophage to Phase 3

The latest update is out from Armata Pharmaceuticals ( (ARMP) ).

On January 13, 2026, Armata Pharmaceuticals announced it had received an End-of-Phase 2 written response from the U.S. Food and Drug Administration supporting advancement of its intravenously administered Staphylococcus aureus bacteriophage candidate, AP-SA02, into a Phase 3 superiority study in complicated S. aureus bacteremia, targeted to start in the second half of 2026. The FDA’s Center for Biologics Evaluation and Research agreed that safety and efficacy data from Armata’s Phase 2a diSArm study, whose results were reported in May 2025 and highlighted at IDWeek 2025 in October 2025, justify progression to a pivotal trial that will test AP-SA02 plus best available antibiotic therapy against standard care alone and evaluate clinical response as the primary endpoint, positioning Armata as the first bacteriophage company to move a clinical candidate into Phase 3 and underscoring its potential to reshape treatment of severe S. aureus bacteremia with the backing of U.S. Department of Defense funding and support from key shareholder Innoviva.

The most recent analyst rating on (ARMP) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.

Spark’s Take on ARMP Stock

According to Spark, TipRanks’ AI Analyst, ARMP is a Neutral.

The score is held down primarily by weak financial performance (large ongoing losses, heavy cash burn, and a strained balance sheet with high debt and negative equity). Technicals provide a partial offset with a strong uptrend and positive MACD, while valuation remains unfavorable due to unprofitability and no dividend yield support.

To see Spark’s full report on ARMP stock, click here.

More about Armata Pharmaceuticals

Armata Pharmaceuticals, Inc., listed on NYSE American, is a late clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics targeting antibiotic-resistant and difficult-to-treat bacterial infections. Leveraging proprietary phage-based technology and in-house cGMP manufacturing, the company is advancing a pipeline of natural and synthetic phage candidates against pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus, with a focus on moving its products from bench to clinic toward full commercialization.

Average Trading Volume: 293,767

Technical Sentiment Signal: Buy

Current Market Cap: $256.7M

For a thorough assessment of ARMP stock, go to TipRanks’ Stock Analysis page.